Children with Lennox-Gastaut syndrome (LGS) who were treated with the cannabinoid product Epidiolex (cannabidiol) had fewer drop seizures, according to results of a clinical trial developed by Britain’s GW Pharmaceuticals.
The Phase 3 trial (GWPCARE3, NCT02224560) showed that patients taking Epidiolex saw the number of monthly seizures fall by 50 percent or more, compared to the 15 percent reported by those on a placebo. Furthermore, the number of patients and caregivers reporting an improvement in the patient’s overall condition was higher among those treated with Epidiolex (66 percent in the low-dose group, 57 percent in the high-dose group) than in the placebo group (44 percent).
Patients tolerated Epidiolex well and reported only mild or moderate side effects including sleepiness and reduced appetite. Results will be presented April 25 during the upcoming meeting of the American Academy of Neurology in Boston.
“Lennox-Gastaut syndrome is one of the most challenging types of epilepsy to treat,” said researcher Anup